Record of Safety
Care Oncology physicians in the United States and the U.K. have safely treated over 2000 patients.
Read Our Study
A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology.
Ongoing Clinical Trial
The Care Oncology treatment is validated by an ongoing clinical trial and a proven record of safety.
How We Partner With Oncologists
Care Oncology partners with oncologists and neuro-oncologists to help patients safely use the COC Protocol metabolic cancer treatment as an adjuvant therapy to standard of care.
Medical Director, Care Oncology Clinic USA
Medical Director of Care Oncology Clinic USA
University Notre Dame, ESTEEM Program on Entrepreneurial Studies
Coach It Forward Chuck Charity Health and Wellness Coaching Hub and Resource
10/94 – 12/18
Medical Director of Radiation Oncology Center at CaroMont Cancer Center, Gaston, Gastonia, NC
9/91 – 7/94
Private Practice Radiation Oncologist, Santa Rosa, CA
9/91 – 6/94 Concurrent with above
Developed an out-patient cancer center with a seven member Medical Oncology Group at Santa Memorial Hospital. Opened 6/95
Radiation Oncologist at The Christ Hospital in Private Practice Cincinnati, Ohio
Paul Zhang, M.D., Ph.D. is the founder of the Institute of Integrative BioOncology (I2B). As a physician-scientist, he is board-certified in medical oncology and internal medicine and board-eligible for medical acupuncture. He has more than 10 years of clinical experience and has specialized in medical treatment of gastroenterological, lung, and prostate cancers. As a member of the Society of Integrative Oncology, he strongly advocates the application of evidence-based comprehensive and integrative approaches to treatment and health restoration.
He was named as one of “America’s Top Physicians” in 2008. Dr. Zhang is a well-known researcher and clinician in the areas of cancer stem cells, novel therapies, and solid tumors. He was among the first to define the growth requirements of cancer stem cells. He described the use of a novel class of drugs that induces cancer differentiation and cell death, histone deactylase (HDAC) inhibitors, and Zolinza (vorinostat) was the first FDA-approved HDAC inhibitor. His recent work focuses on the role of cancer stem cells in the response to novel drug combinations. He is a member of the Society of Integrative Oncology.
Zoraida Mendez, M.D.
Languages: Fluent in Spanish and English
October 01, 2002- December 31, 2018 Oncology physician at Salem Regional Medical Center -I was the only oncologist at that facility. Average of twenty five patients per day. Evaluated cases and created the treatments protocols. Did all Oncology inpatient consults.
July,01, 2000 – September 30, 2001 Locum tenems in Oncology for University Hospitals of Cleveland -Part time Emergency Room and Urgent Care physician for University Hospitals of Cleveland.
July,01, 1993- June 30, 2000 Oncology staff physician, Bone marrow transplant Unit Cleveland Clinic Foundation. Cleveland,Ohio.
July 01, 1990-June 30, 1993. Completed Hematology and Oncology Fellowship program at Cleveland Clinic Foundation, Cleveland,Ohio.
July 01, 1988-June 30, 1990. Hospitalist at Saint Elizabeth Hospital of Youngstown,Ohio.
July 01, 1986-June 30, 1988. Completed Residency in Internal Medicine at Saint Elizabeth Hospital of Youngstown.
July 01, 1985-June 30, 1986. Internship at Saint Elizabeth Hospital of Youngstown.
October 30,1984. Obtained Medical Doctorate degree from Universidad Nacional Pedro Henriquez Urena.